Sign Out
The use of Insulin Degludec in pregnant women with diabetes has been investigated in an interventional trial (EXPECT Trial). A moderate amount of clinical trial and post-marketing data in pregnant women indicate no malformative or feto/neonatal toxicity. The treatment with Insulin Degludec may be considered during pregnancy, if clinically needed.
There is no clinical experience with Insulin Degludec during breast-feeding.
